Author:
Ohno T.,Liu S. Q.,Shiba R.,Kim B. S.,Saijo K.
Reference13 articles.
1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto IT, Seipp CA, Simpson C, Reichert CM, Observations on the systemic adminstration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med 313, 1485–1492 (1985)
2. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319, 1676–1680 (1988)
3. Sato T, Sato N, Takahashi S, Koshiba H, Kikuchi K, Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 46, 4384–4389 (1986)
4. Wolfel T, Herr W, Coulie P, Schmitt U, Buschenfelde K -HM, Knuth A, Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54, 636–644 (1993)
5. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF, MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells - evidence for restriction by a dominant HLA-A allele. J Immunol 146, 1692–1699(1991)